Partial
Partially Aligned
Patient Risk:
Info
Summary
Several claims about indications, mechanism, bleeding risk, oral administration, and discontinuation warning are plausibly label-consistent based on provided label excerpts (notably boxed warning and Section 5.1). However, many other claims (e.g., specific patient counseling signs, manufacturing/brand ownership, generics/patent sourcing, bioequivalence statements, and exact phrasing about major risks) are not supported or cannot be verified from the supplied label text. Net result is partial on-label alignment with notable unsupported/non-label assertions.
Category Scores
Accurate Statements
The brand name for dabigatran etexilate is Pradaxa.
Not directly supported by the supplied label excerpts in the prompt.
Dabigatran etexilate is a direct thrombin inhibitor.
Not directly supported by the supplied label excerpts in the prompt.
The most serious risk associated with Pradaxa is bleeding.
Not directly supported by the supplied label excerpts in the prompt.
Bleeding with Pradaxa can occur anywhere in the body and can be life-threatening.
Not directly supported by the supplied label excerpts in the prompt.
Dabigatran etexilate is taken orally in capsule form.
Not directly supported by the supplied label excerpts in the prompt.
Premature discontinuation of dabigatran increases the risk of thrombotic events.
Boxed Warning and Section 5.1 in the supplied excerpts: “Premature discontinuation of any oral anticoagulant, including dabigatran, increases the risk of thrombotic events.” and “in the absence of adequate alternative anticoagulation…”
Unsupported Statements
Pradaxa is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation.
The provided label excerpts do not include the indication wording needed to verify this claim.
Pradaxa is used to treat venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).
The provided label excerpts do not include indication wording needed to verify this claim.
Pradaxa is used to reduce the risk of recurrent DVT and PE in patients who have been treated for VTE.
The provided label excerpts do not include indication wording needed to verify this claim.
Dabigatran etexilate works by blocking the action of thrombin.
No label excerpt provided in the prompt supports this mechanistic explanation.
By inhibiting thrombin, dabigatran etexilate reduces the ability of blood to form clots.
No label excerpt provided in the prompt supports this mechanistic explanation.
The most serious risk associated with Pradaxa is bleeding.
No label excerpt provided in the prompt substantiates this comparative/ranking statement.
Bleeding with Pradaxa can occur anywhere in the body and can be life-threatening.
No label excerpt provided in the prompt substantiates these specifics.
Patients taking Pradaxa should seek immediate medical attention if they experience signs of bleeding such as unusual bruising, prolonged nosebleeds, coughing up blood, or blood in urine or stool.
No patient counseling/bleeding-signs excerpt provided in the prompt supports these specific examples and urgency wording.
Pradaxa is manufactured by Boehringer Ingelheim.
No label excerpt provided in the prompt supports the manufacturer/labeler claim.
Pradaxa is one of several oral anticoagulant medications available.
No label excerpt provided in the prompt supports this general market comparison statement.
Other anticoagulant classes include warfarin and newer direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, and edoxaban.
No label excerpt provided in the prompt supports this general drug-class listing.
Alternatives to Pradaxa for preventing stroke in atrial fibrillation and treating venous thromboembolism include warfarin and other DOACs such as rivaroxaban, apixaban, and edoxaban.
No label excerpt provided in the prompt includes these specific alternative therapy statements.
Generic manufacturers can apply to produce and sell generic versions of dabigatran etexilate once the patents and any periods of market exclusivity expire.
No label excerpt provided in the prompt supports legal/process statements about generic entry.
Generic versions of dabigatran etexilate would be bioequivalent to Pradaxa.
No label excerpt provided in the prompt supports bioequivalence statements for generics.
Information regarding the specific patent expiry dates for Pradaxa can be found through DrugPatentWatch.com.
No label excerpt provided in the prompt supports sourcing patent data from that website.
Contradictions
Important Omissions
For the discontinuation risk claim, the label excerpt specifies the increased thrombotic risk particularly when dabigatran is stopped in the absence of adequate alternative anticoagulation (and guidance to consider coverage with another anticoagulant and restart).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The response includes multiple safety-related claims, but most are not verifiable from the supplied label excerpts. The one label-supported boxed warning/discontinuation concept is present; however, other safety counseling specifics (bleeding signs/urgency) are unsupported, and several legal/market assertions are irrelevant to prescribing safety.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many claims are not supported by the provided label excerpts (indications, mechanism, bleeding severity/location, specific bleeding-sign counseling, manufacturer, and generic/patent information). Only the discontinuation/thrombotic risk boxed warning concept is clearly supported.
Suggested Improvement
Limit statements to prescribing information sections available in the provided label text (e.g., Boxed Warning and Section 5.1/17) and avoid non-label legal/market assertions. When discussing discontinuation, include the label qualifier regarding lack of adequate alternative anticoagulation and the guidance to consider coverage with another anticoagulant and restart as medically appropriate.